الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Anorexia, cachexia syndrome occurs in 30–80% of people with
cancer referred to palliative care. It contributes to impaired quality of
life (QoL), increased morbidity and mortality. Cyproheptadine
hydrochloride (CH) is a histamine antagonist with appetite-stimulating
effect. The probable mechanisms for appetite stimulating effect of this
drug include constant increased energy intake through more desire to
eating and stimulation of growth hormone secretion by deep sleep
induction. Using CH improves the nutritional status in children with
malnutrition in several studies
The aim of this Study: evaluate the effect and tolerability of
cyproheptadine in cancer associated anorexia and cachexia in cancer
patients
Materials and Methods: This randomized controlled clinical
study was carried out in clinical oncology department, Menoufia
University to evaluate the effect of cyproheptadine in cancer
associated anorexia and cachexia in cancer patients treated in clinical
oncology department, Menoufia University presented from january-
2022 to june -2022. 138 patients were recruited in the study and
divided into 2 groups.
Results: There was no significant difference among the studied
groups regarding height, weight, and BMI, hb, albumin, Appetite
score by FACCT, by ESAS and FACCT score at (baseline, 3, 6, 9, 12
months),
● In patients with non-metastatic stage, follow up Hb at (9 and 12
months) were significantly increased among drug arm.
Moreover, follow up appetite score by FACCT at (9 and 12
Summary
96
months) were significantly increased among drug arm. Also,
follow up appetite score by ESAS at (6, 9 and 12 months)
significantly improves among drug arm. Regarding follow up
of FACCT score at (9 and 12 months) there was significant
increase among drug arm than control arm
● In patients with performance<2, follow up Hb at (6, 9 and 12
months) were significantly increased among drug arm
Moreover, follow up appetite score by FACCT at (3, 6, 9 and
12 months) were significantly increased among drug arm. Also,
follow up appetite score by ESAS at (6, 9 and 12 months)
significantly improves among drug arm. Regarding follow up
of FACCT score at (6, 9 and 12 months) there was significant
increase among drug arm than control arm.
● In Patients with non GIT cancer, follow up Hb at 9 months was
significantly increased among drug arm Moreover, follow up
appetite score by ESAS at 12 months was significantly
improves among drug arm
● In Patients who respond to active treatment, follow up Hb at (9
and 12 months) were significantly increased among drug arm.
Moreover, follow up appetite score by ESAS at (9 and 12
months) were significantly improves among drug arm).
Conclusion: Cypryheptadine is safe and tolerable and might be
used in the treatment of cancer anorexia and cachexia syndrome
provided that good selection of suitable patient regarding age, good
performance status, early stage of cancer.